Progress towards the cGMP production of plurip-otent stem cell derived red blood cells

induction overall response (OR)¼85%, partial response (PR)¼65%, very good PR (VGPR)¼20%, stable disease (SD)¼5% and refractory disease (RD)¼10%. Improvement post autograft to PR¼35%, VGPR¼40% and complete response (CR) ¼10%.Atamedianfollow-upof34(16-45)months,bestresponseachieved is PR¼20%, VGPR¼30% and CR¼40%. In responders best response was achieved post induction in 17%, post autograft in 39% and during maintenance in 44%. Presently 9 (45%) patients continue on maintenance having received a median of 21 (3-45) cycles. Low dose lenalidomide and dexamethasone induction followed by HSCT in untreated myeloma patients is associated with high response rates. Depth of response is improved by HSCT and maintenance treatment. Collection of haematopoietic and dendritic cell precursors is not impaired.